{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:32:50Z","timestamp":1790634770771,"version":"4.1.0"},"reference-count":114,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["UID\/00772\/2025"],"award-info":[{"award-number":["UID\/00772\/2025"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"award":["UID\/00772\/2025"],"award-info":[{"award-number":["UID\/00772\/2025"]}],"id":[{"id":"https:\/\/ror.org\/00snfqn58","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Androgen receptor (AR) signaling has emerged as a potential molecular target in triple-negative breast cancer (TNBC), a clinically aggressive and biologically heterogeneous subtype of breast cancer with limited targeted treatment options. Androgens, the main ligands of AR, have been reported to exert antiproliferative and anti-estrogenic effects in normal mammary epithelium; however, the role of AR signaling in TNBC remains controversial and appears to depend strongly on tumor molecular context. In certain experimental settings, elevated androgen levels have been associated with reduced tumor growth, whereas AR activation has also been linked to signaling pathways involved in cell survival, migration, and invasiveness. AR signaling can occur through classical androgen-dependent mechanisms, as well as through ligand-independent activation mediated by protein kinases and intracellular pathways. Increasing interest in AR biology has led to the evaluation of several anti-androgen therapies in AR-positive TNBC, including agents such as enzalutamide, enobosarm, orteronel, bicalutamide, and seviteronel. Although clinical activity has generally been modest, these studies highlight the potential relevance of AR-targeted strategies in selected patient subgroups. This review summarizes current knowledge on androgen and AR signaling in TNBC, integrating molecular mechanisms, preclinical evidence, and clinical studies, and discusses emerging therapeutic strategies aimed at improving patient treatment outcomes.<\/jats:p>","DOI":"10.3390\/cells15090834","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:06:21Z","timestamp":1777860381000},"page":"834","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An Update on the Role of Androgens and Androgen Receptor in Triple-Negative Breast Cancer"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5383-6184","authenticated-orcid":false,"given":"Belen Crespo","family":"Cortes","sequence":"first","affiliation":[{"name":"Department Animal Physiology, Veterinary Medicine School, Complutense University of Madrid (UCM), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6130-8381","authenticated-orcid":false,"given":"Felisbina L.","family":"Queiroga","sequence":"additional","affiliation":[{"name":"CECAV, Department of Veterinary Sciences, University of Tr\u00e1s-os-Montes and Alto Douro, 5001-801 Vila Real, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Illera","sequence":"additional","affiliation":[{"name":"Department Animal Physiology, Veterinary Medicine School, Complutense University of Madrid (UCM), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6947-2127","authenticated-orcid":false,"given":"Sara Caceres","family":"Ramos","sequence":"additional","affiliation":[{"name":"Department Animal Physiology, Veterinary Medicine School, Complutense University of Madrid (UCM), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple-negative breast cancer therapy: Current and future perspectives (Review)","volume":"57","author":"Won","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"115545","DOI":"10.1016\/j.bcp.2023.115545","article-title":"Triple-negative breast cancer: Epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies","volume":"212","author":"Karim","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Vagia, E., Mahalingam, D., and Cristofanilli, M. (2020). The landscape of targeted therapies in TNBC. Cancers, 12.","DOI":"10.3390\/cancers12040916"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1631\/jzus.B2200113","article-title":"Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: Molecular, morphological, and clinical features","volume":"23","author":"Vtorushin","year":"2022","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Dieci, M.V., Tsvetkova, V., Griguolo, G., Miglietta, F., Mantiero, M., Tasca, G., Cumerlato, E., Giorgi, C.A., Giarratano, T., and Faggioni, G. (2019). Androgen receptor expression and association with distant disease-free survival in triple-negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00452"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"46482","DOI":"10.18632\/oncotarget.10208","article-title":"Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","article-title":"Triple-negative breast cancer: Promising prognostic biomarkers currently in development","volume":"21","author":"Sukumar","year":"2021","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Chaudhuri, A., Kumar, D.N., Dehari, D., Patil, R., Singh, S., Kumar, D., and Agrawal, A.K. (2023). Endorsement of TNBC biomarkers in precision therapy by nanotechnology. Cancers, 15.","DOI":"10.3390\/cancers15092661"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"105439","DOI":"10.1016\/j.jsbmb.2019.105439","article-title":"Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review","volume":"194","author":"Schiffer","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.20945\/2359-3997000000438","article-title":"Classic and current concepts in adrenal steroidogenesis: A reappraisal","volume":"66","author":"Kater","year":"2022","journal-title":"Arch. Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00441-022-03707-9","article-title":"Sex steroid hormone synthesis, metabolism, and the effects on the mammalian olfactory system","volume":"391","author":"Abaffy","year":"2022","journal-title":"Cell Tissue Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101665","DOI":"10.1016\/j.beem.2022.101665","article-title":"Basics of androgen synthesis and action","volume":"36","author":"Elzenaty","year":"2022","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100856","DOI":"10.1016\/j.yfrne.2020.100856","article-title":"Progesterone\u2014Friend or foe?","volume":"59","author":"Comasco","year":"2020","journal-title":"Front. Neuroendocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kasarinaite, A., Sinton, M., Saunders, P.T.K., and Hay, D.C. (2023). The influence of sex hormones in liver function and disease. Cells, 12.","DOI":"10.3390\/cells12121604"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.04.010","article-title":"Androgens in prostate cancer: A tale that never ends","volume":"516","author":"Hou","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s43032-022-00932-z","article-title":"Synthesis, regulatory factors, and signaling pathways of estrogen in the ovary","volume":"30","author":"Xiao","year":"2022","journal-title":"Rep. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Rocha-Rodrigues, S., Sousa, M., Reis, P.L., Leao, C., Cardoso-Marinho, B., Massada, M., and Afonso, J. (2021). Bidirectional interactions between the menstrual cycle, exercise training, and macronutrient intake in women: A review. Nutrients, 13.","DOI":"10.3390\/nu13020438"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"109335","DOI":"10.1016\/j.steroids.2023.109335","article-title":"Estrogen sulfotransferase and sulfatase in steroid homeostasis, metabolic disease, and cancer","volume":"201","author":"Wang","year":"2023","journal-title":"Steroids"},{"key":"ref_19","first-page":"240","article-title":"Steroidogenesis in castration-resistant prostate cancer","volume":"41","author":"Shiota","year":"2023","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Suminska, M., Bogusz-G\u00f3rna, K., Wegner, D., and Fichna, M. (2020). Non-classic disorder of adrenal steroidogenesis and clinical dilemmas in 21-hydroxylase deficiency combined with backdoor androgen pathway: Mini-review and case report. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134622"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"111239","DOI":"10.1016\/j.mce.2021.111239","article-title":"Adrenal androgens, adrenarche, and zona reticularis: A human affair?","volume":"528","author":"Dumontet","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1210\/endrev\/bnab009","article-title":"Normal and premature adrenarche","volume":"42","author":"Rosenfield","year":"2021","journal-title":"Endocr. Rev."},{"key":"ref_23","first-page":"105758","article-title":"The role of androgens in women\u2019s health and wellbeing","volume":"171","author":"Bianchi","year":"2021","journal-title":"Phamacol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tang, J., Chen, L.-R., and Chen, K.-H. (2021). The utilization of dehydroepiandrosterone as a sexual hormone precursor in premenopausal and postmenopausal women: An overview. Pharmaceuticals, 15.","DOI":"10.3390\/ph15010046"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/cen.14710","article-title":"Approach to androgen excess in women: Clinical and biochemical insights","volume":"97","author":"Cussen","year":"2022","journal-title":"Clin. Endocrinol."},{"key":"ref_26","first-page":"142","article-title":"Androgenic steroid excess in women","volume":"85","author":"Karila","year":"2024","journal-title":"Endocr. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"bqac218","DOI":"10.1210\/endocr\/bqac218","article-title":"Adrenal steroids and resistance to hormonal blockade of prostate and breast cancer","volume":"164","author":"Michael","year":"2023","journal-title":"Endocrinology"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dominguez-Lopez, I., Yago-Aragon, M., Salas-Huetos, A., Tresserra-Rimbau, A., and Hurtado-Barroso, S. (2020). Effects of dietary phytoestrogens on hormones throughout a human lifespan: A review. Nutrients, 12.","DOI":"10.3390\/nu12082456"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41574-022-00742-y","article-title":"Hormonal regulation of mammary gland development and lactation","volume":"19","author":"Hannan","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chiodo, C., Morelli, C., Cavaliere, F., Sisci, D., and Lanzino, M. (2022). The other side of the coin: May androgens have a role in breast cancer risk?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010424"},{"key":"ref_31","first-page":"303","article-title":"Research Progress in Androgen Receptor and Triple Negative Breast Cancer","volume":"45","year":"2023","journal-title":"Acta Acad. Med. Sin."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Honma, N., Matsuda, Y., and Mikami, T. (2021). Carcinogenesis of triple-negative breast cancer and sex steroid hormones. Cancers, 13.","DOI":"10.3390\/cancers13112588"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Treeck, O., Sch\u00fcler-Toprak, S., and Ortmann, O. (2020). Estrogen actions in triple-negative breast cancer. Cells, 9.","DOI":"10.3390\/cells9112358"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Alonso-Diez, A., Caceres, S., Pe\u00f1a, L., Crespo, B., and Illera, J.C. (2021). Anti-angiogenic treatments interact with steroid secretion in inflammatory breast cancer triple-negative cell lines. Cancers, 13.","DOI":"10.3390\/cancers13153668"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Crespo, B., Illera, J.C., Silvan, G., Lopez-Plaza, P., Herrera de la Muela, M., de la Puente Yag\u00fce, M., Diaz del Arco, C., Illera, M.J., and Caceres, S. (2024). Androgen and estrogen \u03b2 receptor expression enhances efficacy of antihormonal treatments in triple-negative breast cancer cell lines. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031471"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1007\/s11033-022-07288-2","article-title":"The functional significance and cross-talk of non-coding RNAs in triple-negative and quadruple-negative breast cancer","volume":"49","author":"Paul","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Caceres, S., Monsalve, B., Alonso-Diez, A., Crespo, B., Illera, M.J., de Andres, P.J., Silvan, G., and Illera, J.C. (2021). Blocking estrogen synthesis leads to different hormonal responses in canine and human triple-negative inflammatory breast cancer. Cancers, 13.","DOI":"10.3390\/cancers13194967"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zerdan, M.B., Ghorayeb, T., Saliba, F., Allam, S., Zerdan, M.B., Yaghi, M., Bilani, N., Jaafar, R., and Nahleh, Z. (2022). Triple negative breast cancer: Updates on classification and treatment in 2021. Cancers, 14.","DOI":"10.3390\/cancers14051253"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Crespo, B., Illera, J.C., Lopez-Plaza, P., Herrera de la Muela, M., Puente Yague, M., Diaz del Arco, C., De Andr\u00e9s, P.J., Illera, M.J., and Caceres, S. (2024). Bicalutamide Enhances Conventional Chemotherapy in In Vitro and In Vivo Assays Using Human and Canine Inflammatory Mammary Cancer Cell Lines. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147923"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Kirkby, M., Popatia, A.M., Lavoie, J.R., and Wang, L. (2023). The potential of hormonal therapies for treatment of triple-negative breast cancer. Cancers, 15.","DOI":"10.3390\/cancers15194702"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Khadela, A., Chavda, V.P., Soni, S., Megha, K., Pandya, A.J., and Vora, L. (2023). Anti-androgenic therapies targeting the luminal androgen receptor of a typical triple-negative breast cancer. Cancers, 15.","DOI":"10.3390\/cancers15010233"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Aurilio, G., Cimadamore, A., Mazzucchelli, R., Lopez-Beltran, A., Verri, E., Scarpelli, M., Massari, F., Cheng, L., Santoni, M., and Montironi, R. (2020). Androgen receptor signaling pathway in prostate cancer: From genetics to clinical applications. Cells, 9.","DOI":"10.3390\/cells9122653"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"\u00d6zturan, D., Morova, T., and Lack, N.A. (2022). Androgen receptor-mediated transcription in prostate cancer. Cells, 11.","DOI":"10.3390\/cells11050898"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kraemer, W.J., Ratamess, N.A., Hymer, W.C., Nindl, B.C., and Fragala, M.S. (2020). Growth hormone(s), testosterone, insulin-like growth factors, and cortisol: Roles and integration for cellular development and growth with exercise. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00033"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Caceres, S., Crespo, B., Herrera, M., Puente, M., Diez-Arco, M., Alonso-Diez, A., Illera, M.J., and Illera, J.C. (2025). Androgen receptor activation promotes tumor progression in canine and human triple negative breast cancer cell lines. Front. Vet. Sci., 12.","DOI":"10.3389\/fvets.2025.1677830"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5534\/wjmh.180040","article-title":"Role of Androgen Receptor in Prostate Cancer: A Review","volume":"37","author":"Fujita","year":"2018","journal-title":"World J. Men\u2019s Health"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Anestis, A., Zoi, I., Papavassiliou, A.G., and Karamouzis, M.V. (2020). Androgen receptor in breast cancer\u2014Clinical and preclinical research insights. Molecules, 25.","DOI":"10.3390\/molecules25020358"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"140","DOI":"10.32471\/exp-oncology.2312-8852.vol-42-no-2.14579","article-title":"Prognostic role of androgen receptor expression in patients with metastatic triple-negative breast cancer","volume":"42","author":"Lyalkin","year":"2020","journal-title":"Exp. Oncol."},{"key":"ref_50","first-page":"10008","article-title":"Clinical significance of androgen receptor expression in triple-negative breast cancer\u2014An immunohistochemistry study","volume":"15","author":"Liu","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.currproblcancer.2016.09.004","article-title":"Targeting the androgen receptor in triple-negative breast cancer","volume":"40","author":"Gucalp","year":"2016","journal-title":"Curr. Probl. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1038\/sj.onc.1209415","article-title":"An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen","volume":"25","author":"Doane","year":"2006","journal-title":"Oncogene"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"221","DOI":"10.32604\/or.2023.028525","article-title":"Targeting triple-negative breast cancer: A clinical perspective","volume":"31","author":"Popovic","year":"2023","journal-title":"Oncol. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41591-020-01168-7","article-title":"The androgen receptor is a tumor suppressor in estrogen receptor\u2013positive breast cancer","volume":"27","author":"Hickey","year":"2021","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12672-015-0232-3","article-title":"Androgen Receptor Biology in Triple Negative Breast Cancer: A Case for Classification as AR+ or Quadruple Negative Disease","volume":"6","author":"Barton","year":"2015","journal-title":"Horm. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/OTT.S379867","article-title":"Potential therapeutic targets for luminal androgen receptor breast cancer: What we know so far","volume":"16","author":"Stella","year":"2023","journal-title":"OncoTargets Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/CM9.0000000000002930","article-title":"Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer","volume":"137","author":"Xu","year":"2023","journal-title":"Chin. Med. J. (Engl.)"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13046-017-0545-x","article-title":"ER\u03b21 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1","volume":"36","author":"Song","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","article-title":"Targeting the PI3-kinase pathway in triple-negative breast cancer","volume":"30","author":"Pascual","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zamagni, A., Cortesi, M., Zanoni, M., and Tesei, A. (2019). Non-nuclear AR signaling in prostate cancer. Front. Chem., 7.","DOI":"10.3389\/fchem.2019.00651"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"215775","DOI":"10.1016\/j.canlet.2022.215775","article-title":"Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease","volume":"547","author":"Mehlich","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_62","first-page":"517","article-title":"Research advances and new challenges in overcoming triple-negative breast cancer","volume":"4","author":"Zong","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.7150\/jca.67536","article-title":"Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: A single institution study","volume":"13","author":"Sridhar","year":"2022","journal-title":"J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41416-022-01849-9","article-title":"Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer","volume":"127","author":"Michmerhuizen","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41379-021-00924-5","article-title":"Androgen receptor splicing variant-7 in breast cancer: Clinical and pathologic correlations","volume":"35","author":"Ferguson","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"44728","DOI":"10.18632\/oncotarget.6296","article-title":"Expression of androgen receptor splice variants in clinical breast cancers","volume":"6","author":"Hickey","year":"2015","journal-title":"Oncotarget"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Zheng, Z., Li, J., Liu, Y., Shi, Z., Xuan, Z., Yang, K., Xu, C., Bai, Y., Fu, M., and Xiao, Q. (2022). The crucial role of AR-V7 in enzalutamide-resistance of castration-resistant prostate cancer. Cancers, 14.","DOI":"10.3390\/cancers14194877"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Ben-Dror, J., Shalamov, M., and Sonnenblick, A. (2022). The history of early breast cancer treatment. Genes, 13.","DOI":"10.3390\/genes13060960"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/2211738507666190122111224","article-title":"Drug combinations in breast cancer therapy","volume":"7","author":"Fisusi","year":"2019","journal-title":"Pharm. Nanotechnol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.mce.2018.10.019","article-title":"The role of 17\u03b2HSDs in breast tissue and breast cancers","volume":"489","author":"McNamara","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/1535-7163.MCT-20-0807","article-title":"Activity of combined androgen receptor antagonism and cell cycle inhibition in androgen receptor-positive triple-negative breast cancer","volume":"20","author":"Christenson","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1158\/1078-0432.CCR-12-3327","article-title":"Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer","volume":"19","author":"Gucalp","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_75","unstructured":"(2024, October 14). (2013, June\u20132024, February). Safety and Efficacy Study of Enzalutamide in Patients with Advanced, Androgen Receptor-positive, Triple Negative Breast Cancer (Identifier NCT01889238). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01889238."},{"key":"ref_76","unstructured":"Abramson, V. (2024, October 16). (2015, May\u20132022, August). Taselisib and Enzalutamide in Treating Patients with Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer (Identifier NCT02457910). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02457910."},{"key":"ref_77","unstructured":"Yam, C. (2024, October 10). (2016, February\u20132024, July). Enzalutamide and Paclitaxel Before Surgery in Treating Patients with Stage I\u2013III Androgen Receptor-Positive Triple-Negative Breast Cancer (Identifier NCT02689427). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02689427."},{"key":"ref_78","unstructured":"Karuturi, M. (2025, September 25). (2019, June\u20132023, December). Alpelisib and Enzalutamide in Treating Patients with Androgen Receptor and PTEN Positive Metastatic Breast Cancer (Identifier NCT03207529). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03207529."},{"key":"ref_79","unstructured":"Rugo, H.S. (2025, September 28). (2015, February\u20132020, October). Efficacy and Safety of GTx-024 in Patients with Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) (Identifier NCT02368691). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02368691."},{"key":"ref_80","unstructured":"Yuan, Y. (2025, October 30). (2016, November\u20132024, February). Pembrolizumab and Enobosarm in Treating Patients with Androgen Receptor Positive Metastatic Triple Negative Breast Cancer (Identifier NCT02971761). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02971761."},{"key":"ref_81","unstructured":"Burris, H.A., and SCRI Development Innovations, LLC (2025, October 30). (2013, November\u20132022, June). Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR) (Identifier NCT01990209). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01990209."},{"key":"ref_82","unstructured":"Traina, T.A., and Memorial Sloan Kettering Cancer Center (2026, February 02). (2007, May\u20132021, June). Bicalutamide in Treating Patients with Metastatic Breast Cancer (Identifier NCT00468715). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00468715."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Yuan, Y., Lee, J.S., Yost, S.E., Frankel, P.H., Ruel, C., Egelston, C.A., Guo, W., Gillece, J.D., Folkerts, M., and Reining, L. (2020). A phase II clinical trial of pembrolizumab and enobosarm in patients with androgen receptor-positive metastatic triple-negative breast cancer. Oncologist, 26.","DOI":"10.1002\/onco.13583"},{"key":"ref_84","unstructured":"Gucalp, A. (2026, January 08). (2015, November\u20132025, November). Palbociclib in Combination with Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) (Identifier NCT02605486). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02605486."},{"key":"ref_85","unstructured":"Wisinski, K. (2026, January 09). (2017, March\u20132025, September). Ribociclib and Bicalutamide in AR+ TNBC (Identifier NCT03090165). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03090165."},{"key":"ref_86","unstructured":"Neven, P., Tegen, K.O., and Lilly, E. (2026, January 20). (2024, April\u20132027, December). Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-Positive Triple-Negative Breast Cancer (ABBICAR) (Identifier NCT06365788). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06365788."},{"key":"ref_87","unstructured":"Brown, V. (2026, February 22). (2015, October\u20132019, January). CYP17 Lyase and Androgen Receptor Inhibitor Treatment with Seviteronel Trial (INO-VT-464-006; NCT02580448) (CLARITY-01) (Identifier NCT02580448). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02580448."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41523-020-00190-9","article-title":"Are we there yet? Understanding androgen receptor signaling in breast cancer","volume":"6","author":"Michmerhuizen","year":"2020","journal-title":"npj Breast Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Choupani, E., Madjd, Z., Saraygord-Afshari, N., Kiani, J., and Hosseini, A. (2022). Combination of androgen receptor inhibitor enzalutamide with the CDK4\/6 inhibitor ribociclib in triple-negative breast cancer cells. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0279522"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal therapy for prostate cancer","volume":"42","author":"Desai","year":"2021","journal-title":"Endocr. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Gupta, G.K., Collier, A.L., Lee, D., Hoefer, R.A., Zheleva, V., Siewertsz, L.L., Tang-Tan, A.M., Guye, M.L., Chang, D.Z., and Winston, J.S. (2020). Perspectives on triple-negative breast cancer: Current treatment strategies, unmet needs, and potential targets for future therapies. Cancers, 12.","DOI":"10.3390\/cancers12092392"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00223-019-00613-1","article-title":"The selective androgen receptor modulator ostarine improves bone healing in ovariectomized rats","volume":"106","author":"Komrakova","year":"2020","journal-title":"Calcif. Tissue Int."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1470-2045(24)00004-4","article-title":"Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, estrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): A randomized, open-label, multicenter, multinational, parallel design, phase 2 trial","volume":"25","author":"Palmieri","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.clbc.2021.10.011","article-title":"A phase II study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic breast cancer (MBC)","volume":"22","author":"Yardley","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Chen, M.-K., Liang, Z.-J., Luo, D.-S., Xue, K.-Y., Liao, D.-Y., Li, Z., Yu, Y., Chen, Z.-S., and Zhao, S.-C. (2022). Abiraterone, orteronel, enzalutamide, and docetaxel: Sequential or combined therapy?. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.843110"},{"key":"ref_96","first-page":"e21970","article-title":"Advancements in the treatment of triple-negative breast cancer: A narrative review of the literature","volume":"14","author":"Landry","year":"2022","journal-title":"Cureus"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Rice, M.A., Malhotra, S.V., and Stoyanova, T. (2019). Second-generation antiandrogens: From discovery to standard of care in castration-resistant prostate cancer. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00801"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ajpath.2022.01.010","article-title":"Inhibition of cyclin-dependent kinase 8\/cyclin-dependent kinase 19 suppresses its pro-oncogenic effects in prostate cancer","volume":"192","author":"Offermann","year":"2022","journal-title":"Am. J. Pathol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bulcan.2019.12.012","article-title":"Androgen receptor-positive triple negative breast cancer: From biology to therapy","volume":"107","author":"Grellety","year":"2020","journal-title":"Bull. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"477","DOI":"10.24272\/j.issn.2095-8137.2020.095","article-title":"Breast cancer animal models and applications","volume":"41","author":"Zeng","year":"2020","journal-title":"Zool. Res."},{"key":"ref_101","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"73","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-0716-2376-3_4","article-title":"Breast cancer xenograft murine models","volume":"2508","author":"Fernando","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1158\/0008-5472.CAN-14-3510","article-title":"Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-\/-IL2R\u03b3null immunodeficient mice","volume":"75","author":"Sanmamed","year":"2015","journal-title":"Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1242\/dmm.028274","article-title":"In vivo models in breast cancer research: Progress, challenges and future directions","volume":"10","author":"Holen","year":"2017","journal-title":"Dis. Models Mech."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10549-017-4548-2","article-title":"Canine invasive mammary carcinomas as models of human breast cancer. Part 1: Natural history and prognostic factors","volume":"167","author":"Nguyen","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Salas, Y., Marquez, A., Diaz, D., and Romero, L. (2015). Epidemiological study of mammary tumors in female dogs diagnosed during the period 2002\u20132012: A growing animal health problem. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127381"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Valdivia, G., Alonso-Diez, A., Perez-Alenza, D., and Pe\u00f1a, L. (2021). From conventional to precision therapy in canine mammary cancer: A comprehensive review. Front. Vet. Sci., 8.","DOI":"10.3389\/fvets.2021.623800"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Goncalves, J.P.L., Bollwein, C., Noske, A., Jacob, A., Jank, P., Loibl, S., Nekljudova, V., Fasching, P.A., Karn, T., and Marm\u00e9, F. (2023). Characterization of hormone receptor and HER2 status in breast cancer using mass spectrometry imaging. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032860"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"De Andr\u00e9s, P.J., Caceres, S., Illera, J.C., Crespo, B., Silvan, G., Queiroga, F.L., Illera, M.J., P\u00e9rez-Alenza, M.D., and Pe\u00f1a, L. (2022). Hormonal homologies between canine mammary cancer and human breast cancer in a series of cases. Vet. Sci., 9.","DOI":"10.3390\/vetsci9080395"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Ferreira, T., Gama, A., Seixas, F., Faustino-Rocha, A.I., Lopes, C., Gaspar, V.M., Mano, J.F., Medeiros, R., and Oliveira, P.A. (2023). Mammary glands of women, female dogs and female rats: Similarities and differences to be considered in breast cancer research. Vet. Sci., 10.","DOI":"10.3390\/vetsci10060379"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Caceres, S., Pe\u00f1a, L., de Andres, P.J., Illera, M.J., Lopez, M.S., Woodward, W.A., Reuben, J.M., and Illera, J.C. (2015). Establishment and characterization of a new cell line of canine inflammatory mammary cancer: IPC-366. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122277"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/vco.12238","article-title":"Canine cell line, IPC-366, as a good model for the study of inflammatory breast cancer","volume":"15","author":"Caceres","year":"2017","journal-title":"Vet. Comp. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rvsc.2023.05.014","article-title":"The inhibition of steroid hormones determines the fate of IPC-366 tumor cells, highlighting the crucial role of androgen production in tumor processes","volume":"161","author":"Crespo","year":"2023","journal-title":"Res. Vet. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Ravaioli, S., Maltoni, R., Pasculli, B., Parrella, P., Giudetti, A.M., Vergara, D., Tumedey, M.M., Pirini, F., and Bravaccini, S. (2022). Androgen receptor in breast cancer: The \u201c5W\u201d questions. Front. Endocrinol., 30.","DOI":"10.3389\/fendo.2022.977331"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/9\/834\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:15:24Z","timestamp":1777860924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/9\/834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":114,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cells15090834"],"URL":"https:\/\/doi.org\/10.3390\/cells15090834","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]}}}